Novel PET/SPECT probes for imaging of tau in alzheimer's disease

Scientific World Journal

Volumn 2015, Issue , 2015, Pages

  Watanabe, Hiroyuki ^a   Ono, Masahiro ^a   Saji, Hideo ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTHIAZOLE DERIVATIVE; CARBOLINE DERIVATIVE; QUINOLINE DERIVATIVE; TAU PROTEIN;

ALZHEIMER DISEASE; CLINICAL EVALUATION; CLINICAL RESEARCH; CORRELATIONAL STUDY; DISEASE COURSE; HUMAN; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; DIAGNOSTIC IMAGING; METABOLISM; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY;

ALZHEIMER DISEASE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84927153594     PISSN: 23566140     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2015/124192     Document Type: Review

References (44)

1. E. Johnson, R. Brookmeyer, and K. Ziegler-Graham,"Modeling the effect of Alzheimer's disease on mortality," International Journal of Biostatistics, vol. 3, pp. 186-191, 2007.
2. D. J. Selkoe,"Preventing alzheimer's disease," Science, vol. 337, no. 6101, pp. 1488-1492, 2012.
3. W. E. Klunk,"Biological markers of Alzheimer's disease," Neurobiology of Aging, vol. 19, no. 2, pp. 145-147, 1998.
4. D. J. Selkoe,"Alzheimer's disease: genes, proteins, and therapy," Physiological Reviews, vol. 81, no. 2, pp. 741-766, 2001.
5. C. A. Mathis, B. J. Lopresti, and W. E. Klunk,"Impact of amyloid imaging on drug development in Alzheimer's disease," Nuclear Medicine and Biology, vol. 34, no. 7, pp. 809-822, 2007.
6. C. A. Mathis, Y. Wang, and W. E. Klunk,"Imaging β-amyloid plaques and neurofibrillary tangles in the aging human brain," Current Pharmaceutical Design, vol. 10, no. 13, pp. 1469-1492, 2004.
7. A. Nordberg,"PET imaging of amyloid in Alzheimer's disease," Lancet Neurology, vol. 3, no. 9, pp. 519-527, 2004.
8. C. C. Rowe, U. Ackerman, W. Browne et al.,"Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism," The Lancet Neurology, vol. 7, no. 2, pp. 129-135, 2008.
9. W. Zhang, S. Oya, M.-P. Kung, C. Hou, D. L. Maier, and H. F. Kung,"F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Aβ aggregates in the brain," Nuclear Medicine and Biology, vol. 32, no. 8, pp. 799-809, 2005.
10. C. M. Clark, J. A. Schneider, B. J. Bedell et al.,"Use of florbetapir-PET for imaging β-amyloid pathology," The Journal of the American Medical Association, vol. 305, no. 3, pp. 275-283, 2011.
11. S. R. Choi, G. Golding, Z. Zhuang et al.,"Preclinical properties of 18F-AV-45: a PET agent for Aβ plaques in the brain," Journal of Nuclear Medicine, vol. 50, no. 11, pp. 1887-1894, 2009.
12. D. F. Wong, P. B. Rosenberg, Y. Zhou et al.,"In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18)," Journal of Nuclear Medicine, vol. 51, no. 6, pp. 913-920, 2010.
13. M. Koole, D. M. Lewis, C. Buckley et al.,"Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging," Journal of Nuclear Medicine, vol. 50, no. 5, pp. 818-822, 2009.
14. D. A. Wolk, I. D. Grachev, C. Buckley et al.,"Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology," Archives of Neurology, vol. 68, no. 11, pp. 1398-1403, 2011.
15. N. Okamura, T. Suemoto, S. Furumoto et al.,"Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease," Journal of Neuroscience, vol. 25, no. 47, pp. 10857-10862, 2005.
16. M. T. Fodero-Tavoletti, N. Okamura, S. Furumoto et al.," 18FTHK523: a novel in vivo tau imaging ligand for Alzheimer's disease," Brain, vol. 134, no. 4, pp. 1089-1100, 2011.
17. N. Okamura, S. Furumoto, R. Harada et al.,"Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of Tau pathology in Alzheimer disease," Journal of Nuclear Medicine, vol. 54, no. 8, pp. 1420-1427, 2013.
18. P. Giannakopoulos, F. R. Herrmann, T. Bussière et al.,"Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease," Neurology, vol. 60, no. 9, pp. 1495-1500, 2003.
19. T. Gomez-Isla, R. Hollister, H. West et al.,"Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease," Annals of Neurology, vol. 41, no. 1, pp. 17-24, 1997.
20. E. D. Agdeppa, V. Kepe, J. Liu et al.,"Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease," The Journal of Neuroscience, vol. 21, no. 24, article RC189, 2001.
21. G. W. Small, V. Kepe, L. M. Ercoli et al.,"PET of brain amyloid and tau in mild cognitive impairment," The New England Journal of Medicine, vol. 355, no. 25, pp. 2652-2663, 2006.
22. J. Shin, V. Kepe, J. R. Barrio, and G. W. Small,"The merits of FDDNP-PET imaging in Alzheimers Disease," Journal of Alzheimer's Disease, vol. 26, no. 1, pp. 135-145, 2011.
23. N. Okamura, S. Furumoto, M. T. Fodero-Tavoletti et al.,"Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET," Brain, vol. 137, no. 6, pp. 1762-1771, 2014.
24. W. Zhang, J. Arteaga, D. K. Cashion et al.,"A highly selective and specific PET tracer for imaging of tau pathologies," Journal of Alzheimer's Disease, vol. 31, no. 3, pp. 601-612, 2012.
25. C. F. Xia, J. Arteaga, G. Chen et al.,"[18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease," Alzheimer's and Dementia, vol. 9, no. 6, pp. 666-676, 2013.
26. K. Matsumura, M. Ono, S. Hayashi et al.,"Phenyldiazenyl benzothiazole derivatives as probes for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains," Med-ChemComm, vol. 2, no. 7, pp. 596-600, 2011.
27. K. Matsumura, M. Ono, H. Kimura et al.," 18F-labeled phenyldiazenyl benzothiazole for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains," ACSMedicinal Chemistry Letters, vol. 3, no. 1, pp. 58-62, 2012.
28. M. Maruyama, H. Shimada, T. Suhara et al.,"Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls," Neuron, vol. 79, no. 6, pp. 1094-1108, 2013.
29. R. Harada, N. Okamura, S. Furumoto et al.,"Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology," European Journal of Nuclear Medicine and Molecular Imaging, vol. 40, no. 1, pp. 125-132, 2013.
30. C. A. Mathis, Y. Wang, D. P. Holt, G.-F. Huang, M. L. Debnath, and W. E. Klunk,"Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents," Journal of Medicinal Chemistry, vol. 46, no. 13, pp. 2740-2754, 2003.
31. W. E. Klunk, H. Engler, A. Nordberg et al.,"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B," Annals of Neurology, vol. 55, no. 3, pp. 306-319, 2004.
32. Y. Kudo, N. Okamura, S. Furumoto et al.,"2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients," Journal of Nuclear Medicine, vol. 48, no. 4, pp. 553-561, 2007.
33. V. L. Villemagne, S. Furumoto, M. T. Fodero-Tavoletti et al.,"In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease," European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 5, pp. 816-826, 2014.
34. D. T. Chien, A. K. Szardenings, S. Bahri et al.,"Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808," Journal of Alzheimer's Disease, vol. 38, no. 1, pp. 171-184, 2014.
35. D. T. Chien, S. Bahri, A. K. Szardenings et al.,"Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807," Journal of Alzheimer'sDisease, vol. 34, no. 2, pp. 457-468, 2013.
36. N. S. Honson, R. L. Johnson, W. Huang, J. Inglese, C. P. Austin, and J. Kuret,"Differentiating Alzheimer disease-associated aggregates with small molecules," Neurobiology of Disease, vol. 28, no. 3, pp. 251-260, 2007.
37. L. E. Rojo, J. Alzate-Morales, I. N. Saavedra, P. Davies, and R. B. MacCioni,"Selective interaction of lansoprazole and Astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease," Journal of Alzheimer'sDisease, vol. 19, no. 2, pp. 573-589, 2010.
38. P. J. Riss, L. Brichard, V. Ferrari et al.,"Radiosynthesis and characterization of astemizole derivatives as lead compounds toward PET imaging of τ-pathology," MedChemComm, vol. 4, no. 5, pp. 852-855, 2013.
39. X. Shao, G. M. Carpenter, T. J. Desmond et al.,"Evaluation of [11C]N-methyl lansoprazole as a radiopharmaceutical for PET imaging of tau neurofibrillary tangles," ACS Medicinal Chemistry Letters, vol. 3, no. 11, pp. 936-941, 2012.
40. M. V. Fawaz, A. F. Brooks, M. E. Rodnick et al.,"High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection," ACS ChemicalNeuroscience, vol. 5, no. 8, pp. 718-730, 2014.
41. M. Ono, S. Hayashi, K. Matsumura et al.,"Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer's brains," ACS Chemical Neuroscience, vol. 2, no. 5, pp. 269-275, 2011.
42. T. Tago, S. Furumoto, N. Okamura et al.,"Synthesis and preliminary evaluation of 2-arylhydroxyquinoline derivatives for tau imaging," Journal of Labelled Compounds and Radiopharmaceuticals, vol. 57, no. 1, pp. 18-24, 2014.
43. K. Matsumura, M. Ono, M. Yoshimura et al.,"Synthesis and biological evaluation of novel styryl benzimidazole derivatives as probes for imaging of neurofibrillary tangles in Alzheimer's disease," Bioorganic and Medicinal Chemistry, vol. 21, no. 11, pp. 3356-3362, 2013.
44. H. Watanabe, M. Ono, H. Kimura et al.,"Synthesis and biological evaluation of novel oxindole derivatives for imaging neurofibrillary tangles in Alzheimer's disease," Bioorganic and Medicinal Chemistry Letters, vol. 22, no. 17, pp. 5700-5703, 2012.